SPRO stock jumps as FDA clears future regulatory path for UTI candidate (NASDAQ:SPRO)
Spero Therapeutics, Inc. (SPRO) closed ~64% higher Tuesday after the clinical-stage biotech announced that the FDA agreed to review results from a single additional Phase 3 trial to…
SPRO stock jumps as FDA clears future regulatory path for UTI candidate (NASDAQ:SPRO)
Spero Therapeutics, Inc. (SPRO) closed ~64% higher Tuesday after the clinical-stage biotech announced that the FDA agreed to review results from a single additional Phase 3 trial to…